

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/811,563	03/29/2004	Victor L. Serebruany	0004.0001-000	1385	
	7590 10/11/2007 C.G. GIUGLIANO, P.C.		EXAMINER		
100 Cummings Center			PAGONAKIS, ANNA		
Suite 342G Beverly, MA 01915			ART UNIT	PAPER NUMBER	
			4173		

			MAIL DATE	DELIVERY MODE	
			10/11/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
Office Action Commons	10/811,563	SEREBRUANY, VICTOR L.			
Office Action Summary	Examiner	Art Unit			
	Anna Pagonakis	4173			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tiruly apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 1-28 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-28 are subject to restriction and/or expected. Application Papers 9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access	vn from consideration. election requirement.	Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate			

DETAILED ACTION

Due to the complex nature of the claims, no request for oral election is being made. Please see MPEP 812.01.

Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-14, 22, 23 and 27-28, drawn to a method of treating a vascular disorder by selecting an individual having an elevated G-coupled Protease Activating Receptor (PAR)-1 level, an elevated PAR-4 level, or both; and administering an effective amount of statin to an individual.
- II. Claims 15-17 and 24, drawn to a method of treating an individual with a vascular disorder by selecting an individual that has a vascular disorder and by administering an effective amount of statin.
- III. Claims 18-21, and 25-26, drawn to a method of reducing thrombin generation in an individual by selecting an individual that has a vascular disorder and by administering to an individual an effective amount of statin.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-III are directed to related methods of treatment one of a vascular disorder or thrombin generation. The related inventions are distinct if the (1) the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function or effect; (2) the inventions do not overlap in scope, i.e., are mutually exclusive; and (3)

the inventions as claimed encompass related methods of treating a vascular disorder or thrombin generation. For example, the mode of administrations between Groups I, II and III are entirely different. Furthermore, Group III is in regards to treatment of thrombin generation while I-II are directed to treatment of a vascular disorder. As such, the search required for Groups I, II and II would not be the same. Furthermore, the inventions as claimed do not encompass overlapping subject matter and there is nothing of record to show them to be obvious variants.

These inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required. Because the inventions required a different field of search (see MPEP 808.02), restriction for examination purposes as indicated is proper.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claims is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant is entitled must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant is entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of

an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must include which are readable upon the elected species. See MPEP 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species of be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anna Pagonakis whose telephone number is 571-270-3505. The examiner can normally be reached on Monday thru Thursday, 9am to 5pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin H. Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/811,563

Art Unit: 4173

Page 5

10/4/07

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

AP

ARDIN H. MARSCHEL SUPERVISORY PATENT EXAMINER